STOCK TITAN
  1. Home
  2. News
  3. SYBX

Synlogic Inc - SYBX STOCK NEWS

Welcome to our dedicated news page for Synlogic (Ticker: SYBX), a resource for investors and traders seeking the latest updates and insights on Synlogic.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Synlogic's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Synlogic's position in the market.

News
Lineage Announces Appointment of Charlotte Hubbert, Ph.D., as Vice President of Corporate Development
Rhea-AI Summary
Lineage Cell Therapeutics, Inc. appoints Dr. Charlotte Hubbert as Vice President of Corporate Development, bringing extensive experience in cell therapy research and venture investment. Dr. Hubbert's background includes leadership roles at Gates Foundation Venture Capital and NanoString Technologies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.35%
Tags
management
-
News
Synlogic Reports Fourth Quarter and Full Year 2023 Financial Results
Rhea-AI Summary
Synlogic, Inc. (Nasdaq: SYBX) reported financial results for Q4 and full year 2023, with revenue growth and decreased net losses. The company decided to discontinue a pivotal study and explore strategic options.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.32%
Tags
earnings
-
News
Synlogic Adopts Limited Duration Stockholders Rights Plan
Rhea-AI Summary
Synlogic, Inc. engages Ladenburg Thalmann as a financial advisor for its strategic review process. They have approved a limited duration shareholder rights plan and a dividend distribution. The Rights Plan aims to protect stockholders following an unsolicited accumulation of Synlogic shares by an investor. Ladenburg Thalmann will assist in evaluating strategic options to maximize shareholder value.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.94%
Tags
none
News
Synlogic Announces Decision to Discontinue Synpheny-3 Study and Provides Corporate Update
Rhea-AI Summary
Synlogic, Inc. has decided to discontinue its pivotal study of labafenogene marselecobac (SYNB1934) for phenylketonuria (PKU) due to initial data indicating the study was unlikely to meet its primary endpoint. The decision was based on an internal review and not safety concerns. The company plans to explore strategic alternatives to enhance shareholder value. This decision will result in a reduction of the workforce by over 90% and the departure of the President and CEO.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-48.7%
Tags
none
-
News
Synlogic Announces Publication of Preclinical and Clinical Data for SYNB1353 as a Potential Treatment for Classical Homocystinuria
Rhea-AI Summary
Synlogic, Inc. (Nasdaq: SYBX) announced the successful degradation of methionine, precursor to homocysteine, using dietary disease model in preclinical models and healthy volunteer study. SYNB1353 was well-tolerated, with similar proportions in both the placebo and active arms reporting mild-moderate gastrointestinal adverse events.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.29%
Tags
clinical trial
-
News
Synlogic Provides Corporate Update and Outlook for 2024
Rhea-AI Summary
Synlogic, Inc. (SYBX) announced the anticipated key milestones for 2024, including the Data Monitoring Committee review of initial study data from the pivotal Synpheny-3 study in PKU expected in H1 2024, and the top-line, Phase 3 data in PKU expected in H1 2025. The company accomplished several milestones in 2023, including the initiation of the global pivotal Synpheny-3 study, positive results from the Synpheny-1 Phase 2 study, and the receipt of multiple regulatory designations. The company also made significant progress with its other potential treatments for PKU and homocystinuria, secured funding through public offerings, and achieved key milestones in research collaborations.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.6%
Tags
none
News
Synlogic Announces Contract with the Air Force Research Lab
Rhea-AI Summary
Synlogic, Inc. (Nasdaq: SYBX) has secured an approximately $1 million subcontract under an Air Force Research Lab (AFRL) prime contract to develop a manufacturing process for a potential live probiotic product. The project is an extension of previous work initiated by Synlogic in 2020 as part of the Air Force Synthetic Biology Challenge with MIT. The activities are expected to start in Q1 2024 and complete in Q1 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.24%
Tags
none
-
News
Synlogic Announces Abstract Accepted for Poster Presentation at the International Conference on Microbiome Engineering 2023
Rhea-AI Summary
Synlogic, Inc. (Nasdaq: SYBX) announces the acceptance of an abstract outlining the SYNB1353 program as a potential treatment for homocystinuria (HCU), including findings from fermentation process improvements to increase activity of methionine degradation. The poster presentation will be held at the International Conference on Microbiome Engineering 2023, showcasing the improvements of SYNB1353, an Engineered Bacteria for the Treatment of Homocystinuria, leading to increased In vitro and In vivo Degradation of Methionine.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.61%
Tags
none
-
News
Synlogic Reports Third Quarter 2023 Financial Results and Provides Corporate Update
Rhea-AI Summary
Synlogic, Inc. (Nasdaq: SYBX) reported a public offering of $21.0 million, extending cash runway into 2025. Fast Track Designation from the FDA for labafenogene marselecobac (SYNB1934) for PKU. Milestone payment from Roche. Synpheny-3 trial progress supports enrollment completion in 2024, with top-line data in 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-15.02%
Tags
earnings
News
Synlogic Achieves Research Milestone and Earns $2.5 Million Milestone Payment from Roche Collaboration
Rhea-AI Summary
Synlogic, Inc. (Nasdaq: SYBX) has achieved its third pre-specified research milestone and earned a third milestone payment of $2.5 million under its collaboration agreement with Roche for the research and pre-clinical development of a Synthetic Biotic for the treatment of inflammatory bowel disease (IBD). The collaboration aims to address an undisclosed novel target in IBD, with Roche having the exclusive option to enter a licensing and collaboration agreement for further development and commercialization of the product candidate.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.27%
Tags
none
Stock SYBX logo
Synlogic Inc

NYSE:SYBX

SYBX Rankings

#5108 Ranked by Market Cap
#101 Ranked by Stock Gains
N/A Ranked by Dividends

SYBX Stock Data

20.62M
2.90M
10.29%
70.46%
0.33%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Cambridge

About SYBX

at synlogic, we are dedicated to bringing innovative medicines to patients by driving the convergence of two revolutionary fields: synthetic biology and the microbiome. using our synthetic biotics platform, we are engineering probiotic bacteria to perform specific therapeutic functions with established links to disease. we can deliver these synthetic biotics™ orally, where they act from the gut microbiome to correct missing or dysfunctional metabolic activities throughout the body. we also aim to deliver synthetic biotics at the site of disease in cases where local activity is critical, as in stimulation of immune effectors to combat certain tumors. we can rapidly translate this groundbreaking science and technology into medicines that have the potential to change the lives of patients. our lead programs target patients with rare genetic metabolic diseases, including urea cycle disorders (ucd) and phenylketonuria (pku). we are also hard at work on synthetic biotics™ to address more pre